Patents by Inventor Herve Bouchard

Herve Bouchard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210163458
    Abstract: The present invention relates to cryptophycin compounds of formula (I): The invention also relates to cryptophycin payloads, to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The invention also relates to the process for preparing these conjugates.
    Type: Application
    Filed: December 10, 2020
    Publication date: June 3, 2021
    Inventors: Antony BIGOT, Hervé BOUCHARD, Marie-Priscille BRUN, François CLERC, Jidong ZHANG
  • Patent number: 11007275
    Abstract: The present disclosure relates to compounds of formula (V): wherein Ab represents an antibody. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: May 18, 2021
    Assignee: SANOFI
    Inventors: Hervé Bouchard, Marie-Priscille Brun, Philippe Hubert
  • Patent number: 10941139
    Abstract: The present invention relates to cryptophycin compounds of formula (I). The invention also relates to cryptophycin payloads, to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The invention also relates to the process for preparing these conjugates.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: March 9, 2021
    Assignee: SANOFI
    Inventors: Antony Bigot, Hervé Bouchard, Marie-Priscille Brun, François Clerc, Jidong Zhang
  • Publication number: 20200102401
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: September 3, 2019
    Publication date: April 2, 2020
    Inventors: Pierre-Francois BERNE, Francis BLANCHE, Hervé BOUCHARD, Béatrice CAMERON, Tarik DABDOUBI, Stéphanie DECARY, Paul FERRARI, Alexey RAK
  • Publication number: 20200093934
    Abstract: The present disclosure relates to compounds of formula (I): RCG1-L-P (I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.
    Type: Application
    Filed: May 9, 2018
    Publication date: March 26, 2020
    Inventors: Hervé BOUCHARD, Marie-Priscille BRUN, Philippe HUBERT
  • Publication number: 20200054760
    Abstract: The present disclosure relates to compounds of formula (I): RCG1-L-P??(I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.
    Type: Application
    Filed: November 4, 2019
    Publication date: February 20, 2020
    Inventors: Hervé BOUCHARD, Marie-Priscille BRUN, Philippe HUBERT
  • Publication number: 20190382391
    Abstract: The present invention relates to cryptophycin compounds of formula (I). The invention also relates to cryptophycin payloads, to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The invention also relates to the process for preparing these conjugates.
    Type: Application
    Filed: November 3, 2016
    Publication date: December 19, 2019
    Inventors: Antony BIGOT, Hervé BOUCHARD, Marie-Priscille BRUN, Francois CLERC, Jidong ZHANG
  • Patent number: 10457739
    Abstract: Antibodies are provided which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also provided are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising the antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: October 29, 2019
    Assignee: SANOFI
    Inventors: Pierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
  • Publication number: 20180369401
    Abstract: The present disclosure relates to compounds of formula (I): RCG1-L-P??(I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.
    Type: Application
    Filed: May 9, 2018
    Publication date: December 27, 2018
    Inventors: Hervé BOUCHARD, Marie-Priscille BRUN, Philippe HUBERT
  • Publication number: 20180022817
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: March 1, 2017
    Publication date: January 25, 2018
    Inventors: Pierre-Francois BERNE, Francis BLANCHE, Hervé BOUCHARD, Béatrice CAMERON, Tarik DABDOUBI, Stéphanie DECARY, Paul FERRARI, Alexey RAK
  • Patent number: 9676864
    Abstract: The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: June 13, 2017
    Assignee: SANOFI
    Inventors: Herve Bouchard, Alain Commercon, Claudia Fromond, Vincent Mikol, Fabienne Parker, Ingrid Sassoon, Daniel Tavares
  • Patent number: 9617345
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: April 11, 2017
    Assignee: SANOFI
    Inventors: Pierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
  • Publication number: 20160108131
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: May 19, 2015
    Publication date: April 21, 2016
    Inventors: Pierre-Francois BERNE, Francis BLANCHE, Hervé BOUCHARD, Béatrice CAMERON, Tarik DABDOUBI, Stéphanie DECARY, Paul FERRARI, Alexey RAK
  • Publication number: 20150044197
    Abstract: The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.
    Type: Application
    Filed: January 15, 2014
    Publication date: February 12, 2015
    Applicant: Sanofi
    Inventors: Herve BOUCHARD, Alain COMMERCON, Claudia FROMOND, Vincent MIKOL, Fabienne PARKER, Ingrid SASSOON, Daniel TAVARES
  • Patent number: 8952147
    Abstract: Provided herein are cryptophycin conjugates and compositions containing them. Methods of making and using such compounds also are provided.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: February 10, 2015
    Assignee: Sanofi
    Inventors: Hervé Bouchard, Marie-Priscille Brun, Alain Commercon, Jidong Zhang
  • Patent number: 8668910
    Abstract: The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: March 11, 2014
    Assignee: Sanofi
    Inventors: Herve Bouchard, Alain Commercon, Claudia Fromond, Vincent Mikol, Fabienne Parker, Ingrid Sassoon, Daniel Tavares
  • Patent number: 8404678
    Abstract: The invention relates to novel tomaymicine derivatives comprising a linker. It also relates to the conjugate molecules that comprise one or more of said tomaymicine derivatives covalently linked to a cell binding agent through a linking group that is present on the linker of the tomaymycin derivative. It also relates to the preparation of the tomaymicine derivatives and of the conjugate molecules.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: March 26, 2013
    Assignee: Sanofi
    Inventors: Hervé Bouchard, Ravi V. J. Chari, Alain Commerçon, Yonghong Deng, Laurence Gauzy
  • Publication number: 20120276124
    Abstract: The invention relates to a compound of formula (I): wherein: ALK is a (C1-C6)alkylene group; X1 et X2 are each independently one of the following groups: —CH?CH—, —CO—, —CONR—, —NRCO—, —COO—, —OCO—, —OCONR—, —NRCOO—, —NRCONR?—, —NR—, —S(O)n (n=0, 1 or 2) or —O—; R and R? are independently H or a (C1-C6)alkyl group; i is an integer of from 1 to 40, preferably from 1 to 20, and more preferably from 1 to 10; j is an integer corresponding to 1 when X2 is —CH?CH— and 2 when X2 is not —CH?CH—; Zb is a simple bond, —O— or —NH— and Rb is H or a (C1-C6)alkyl, (C3-C7)cycloalkyl, aryl, heteroaryl or (C3-C7)heterocycloalkyl group; or Zb is a single bond and Rb is Hal.
    Type: Application
    Filed: March 29, 2012
    Publication date: November 1, 2012
    Applicant: SANOFI
    Inventors: Hervé BOUCHARD, Alain COMMERCON, Claudia FROMOND, Vincent MIKOL, Fabienne PARKER, Ingrid SASSOON, Daniel TAVARES
  • Patent number: 8288425
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: October 16, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael L. Edwards, Paul J. Cox, Shelley Amendola, Stephanie D. Deprets, Timothy A. Gillespy, Christopher D. Edlin, Andrew D. Morley, Charles J. Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir N. Majid, John C. Reader, Lloyd J. Payne, Nawaz M. Khan, Michael Cherry
  • Publication number: 20120225089
    Abstract: Provided herein are cryptophycin conjugates and compositions containing them. Methods of making and using such compounds also are provided.
    Type: Application
    Filed: December 20, 2011
    Publication date: September 6, 2012
    Applicant: SANOFI
    Inventors: Hervé BOUCHARD, Marie-Priscille BRUN, Alain COMMERCON, Jidong ZHANG